EP4090686A4 - Pro-anticorps réduisant la toxicité hors cible - Google Patents

Pro-anticorps réduisant la toxicité hors cible Download PDF

Info

Publication number
EP4090686A4
EP4090686A4 EP21741991.0A EP21741991A EP4090686A4 EP 4090686 A4 EP4090686 A4 EP 4090686A4 EP 21741991 A EP21741991 A EP 21741991A EP 4090686 A4 EP4090686 A4 EP 4090686A4
Authority
EP
European Patent Office
Prior art keywords
pro
antibody
reduces
target toxicity
toxicity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21741991.0A
Other languages
German (de)
English (en)
Other versions
EP4090686A2 (fr
Inventor
Kuo-Fu TSENG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunelogic Therapeutics Inc
Original Assignee
Immune Targeting Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune Targeting Inc filed Critical Immune Targeting Inc
Priority claimed from PCT/US2021/013688 external-priority patent/WO2021146590A2/fr
Publication of EP4090686A2 publication Critical patent/EP4090686A2/fr
Publication of EP4090686A4 publication Critical patent/EP4090686A4/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP21741991.0A 2020-01-17 2021-01-15 Pro-anticorps réduisant la toxicité hors cible Pending EP4090686A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062962555P 2020-01-17 2020-01-17
PCT/US2021/013688 WO2021146590A2 (fr) 2020-01-17 2021-01-15 Pro-anticorps réduisant la toxicité hors cible

Publications (2)

Publication Number Publication Date
EP4090686A2 EP4090686A2 (fr) 2022-11-23
EP4090686A4 true EP4090686A4 (fr) 2024-03-27

Family

ID=82906067

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21741991.0A Pending EP4090686A4 (fr) 2020-01-17 2021-01-15 Pro-anticorps réduisant la toxicité hors cible

Country Status (2)

Country Link
EP (1) EP4090686A4 (fr)
CN (1) CN114945597A (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021222762A2 (fr) * 2020-04-30 2021-11-04 Aetio Biotherapy, Inc. Composition d'il2 activable et procédés d'utilisation
TW202540200A (zh) 2023-12-01 2025-10-16 美商基利科學股份有限公司 抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途
US20260056209A1 (en) 2024-06-14 2026-02-26 Gilead Sciences, Inc. Anti-ccr8 antibodies and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017156178A1 (fr) * 2016-03-08 2017-09-14 Maverick Therapeutics, Inc. Protéines de liaison inductibles et méthodes d'utilisation
WO2019051102A2 (fr) * 2017-09-08 2019-03-14 Maverick Therapeutics, Inc. Protéines de liaison à activation conditionnelle restreinte

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY33492A (es) * 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
UA117901C2 (uk) * 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
EP3539982B1 (fr) * 2011-12-23 2025-02-19 Pfizer Inc. Régions constantes d'anticorps modifiés pour conjugaison spécifique à un site, et leurs procédés et utilisations
GB201203442D0 (en) * 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
CN110078827A (zh) * 2012-04-27 2019-08-02 西托姆克斯治疗公司 结合表皮生长因子受体的可活化的抗体其使用方法
KR102488220B1 (ko) * 2013-09-25 2023-01-12 싸이톰스 테라퓨틱스, 인크. 매트릭스 메탈로프로테이나제 기질 및 다른 절단성 모이어티 및 이의 사용 방법
WO2016014974A2 (fr) * 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anticorps anti-cd3, anticorps anti-cd3 activables, anticorps anti-cd3 multispécifiques, anticorps anti-cd3 activables multispécifiques et procédés d'utilisation de ces anticorps
HK1250997A1 (zh) * 2015-05-01 2019-01-18 基因泰克公司 掩蔽抗cd3抗体和使用方法
CN107709356A (zh) * 2015-06-26 2018-02-16 南加利福尼亚大学 用于肿瘤特异性活化的掩蔽嵌合抗原受体t细胞
EP3328427B1 (fr) * 2015-07-27 2024-05-29 The General Hospital Corporation Dérivés d'anticorps présentant une fonction effectrice activée de manière conditionnelle
JP7022080B2 (ja) * 2016-05-27 2022-02-17 ジェネンテック， インコーポレイテッド 部位特異的抗体－薬物複合体の特徴付けのための生化学分析的方法
AU2018231127A1 (en) * 2017-03-09 2019-09-19 Cytomx Therapeutics, Inc. CD147 antibodies, activatable CD147 antibodies, and methods of making and use thereof
US11364303B2 (en) * 2017-09-29 2022-06-21 Pfizer Inc. Cysteine engineered antibody drug conjugates
JPWO2020246563A1 (fr) * 2019-06-05 2020-12-10
JP2023518835A (ja) * 2020-03-26 2023-05-08 エショー バイオセラピー， インク． 制御性ｔ細胞の除去用の二重特異性融合タンパク質

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017156178A1 (fr) * 2016-03-08 2017-09-14 Maverick Therapeutics, Inc. Protéines de liaison inductibles et méthodes d'utilisation
WO2019051102A2 (fr) * 2017-09-08 2019-03-14 Maverick Therapeutics, Inc. Protéines de liaison à activation conditionnelle restreinte

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LANG SHANSHAN ET AL: "LegoBody: facile generation of bispecific and multi-specific antibodies", BIORXIV, 27 December 2019 (2019-12-27), XP093129094, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2019.12.25.888586v1.full.pdf> [retrieved on 20240208], DOI: 10.1101/2019.12.25.888586 *

Also Published As

Publication number Publication date
CN114945597A (zh) 2022-08-26
EP4090686A2 (fr) 2022-11-23

Similar Documents

Publication Publication Date Title
AU2021901309A0 (en) Tr3k board
AU2021901191A0 (en) Tre3k board
EM86542970004S (fr) Tiroirs
EM86542970002S (fr) Tiroirs
EM86542970001S (fr) Tiroirs
EM86542970003S (fr) Tiroirs
EM87738570001S (fr) Cibles multi-sports
AU2021904122A0 (en) Playsafe
AU2021903826A0 (en) Iceglass
EM87459210001S (fr) Survêtements
EM87445850004S (fr) Veilleuses [lampes]
EM87288770001S (fr) Pinces de préhension
EM87259640067S (fr) Blousons
AU2021902800A0 (en) Enviro-lid-catch
AU2021902772A0 (en) MyHerculead
EM85951280001S (fr) Veilleuses [lampes]
EM85478890005S (fr) Radiogoniomètres
EM85476240003S (fr) Boîtes isolantes [ménage]
EM85472440001S (fr) Couteaux de poche
EM85347130022S (fr) Chaises longues
EM85205630010S (fr) Présentation
EM85205630007S (fr) Présentation
EM85205630006S (fr) Présentation
EM85205630005S (fr) Présentation
EM84460820019S (fr) Présentation

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220712

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: IMMUNE TARGETING INC.

A4 Supplementary search report drawn up and despatched

Effective date: 20240227

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/58 20060101ALI20240221BHEP

Ipc: A61P 37/02 20060101ALI20240221BHEP

Ipc: A61P 17/06 20060101ALI20240221BHEP

Ipc: A61P 35/00 20060101ALI20240221BHEP

Ipc: C07K 16/30 20060101AFI20240221BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: IMMUNELOGIC THERAPEUTICS, INC.